Drug Trial Radar · NCT05626634
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Nov 8, 2022
Primary completion
Dec 20, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Longboard PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
Conditions
- Developmental and Epileptic Encephalopathy
- Dravet Syndrome
- Lennox-Gastaut Syndrome
Interventions
LP352, bexicaserinDrug
LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent Adverse EventsTime frame: Baseline up to Week 52
- Columbia-Suicide Severity Rating Scale (C-SSRS) ResponseTime frame: Baseline up to Week 52
- Patient Health Questionnaire-9 Total Score and Question 9 ScoreTime frame: Baseline up to Week 52
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Rancho Los Amigos National Rehabilitation Center (RLANRC)
Downey, California
University of California San Francisco
San Francisco, California
Northwest Florida Clinical Research Group
Gulf Breeze, Florida
University of Miami
Miami, Florida
Advent Health Orlando
Orlando, Florida
Research Institute of Orlando
Orlando, Florida
University of South Florida
Tampa, Florida
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Spectrum Health
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Boston Children's Health Physicians LLP
Hawthorne, New York
Northwell Health
New York, New York
Northeast Regional Epilepsy Group
Staten Island, New York
OnSite Clinical Solutions LLC
Charlotte, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Providence Neurological Specialties-East
Portland, Oregon
Child Neurology Consultants of Austin
Austin, Texas
Austin Epilepsy Care Center
Austin, Texas
University of Utah
Salt Lake City, Utah
University of Washington Valley Medical Center
Renton, Washington
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Austin Health
Heidelberg, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.